Akèy › Limfom Difize Gwo Selil B › Wisconsin
Etid klinik pou Limfom Difize Gwo Selil B nan Wisconsin
19 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Wisconsin.
Vil nan Wisconsin
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- ak 18 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT03418038A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- SSM Health Dean Medical Group ( Site 0106), Madison
- Medical College of Wisconsin ( Site 0103), Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- SSM Health Dean Medical Group ( Site 0140), Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of ARC-02 in B-cell NHL
- Froedtert & Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 70 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06594939LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Froedtert & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 a 81 · Tout sèks · Mizajou Aug 6, 2026 · NCT05990465Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Feb 23, 2026 · NCT04186520Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Medical College of Wisconsin, Milwaukee
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT06834373Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 18 a 80 · Tout sèks · Mizajou Nov 10, 2025 · NCT03375619Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- ak 22 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.